CORDIS
EU research results

CORDIS

English EN
Apoptosis Modelling for Treatment Decisions in Colorectal Cancer

Apoptosis Modelling for Treatment Decisions in Colorectal Cancer

Objective

"With the arrival of new colorectal cancer (CRC) therapeutics targeting specific cell signalling pathways, such as anti-EGFR therapy, personalised cancer treatment is at the door step of clinical practise. This progress in drug development contrasts strikingly with current clinical practice, where decision making depends largely on clinical factors such as tumour staging and age of patient, with the success of such treatments being largely unpredictable. 5-FU-based chemotherapy represents the main stay of CRC therapy. DNA damaging agents such as 5-FU and anti-EGFR therapy seek to induce tumour regression through induction of apoptosis or sensitization to apoptosis. Dysfunctional apoptosis is well recognized as a key contributing factor in chemotherapy resistance. The aim of the APODECIDE consortium is to develop systems medicine tools that predict treatment responses in CRC patients to 5-FU-based chemotherapy and anti-EGFR therapy, based on a systems analysis of apoptosis and EGFR signalling pathways. Based on previous clinical proof-of-concept studies that demonstrated the unique potential of such approaches in predicting tumour resistance, the APO-DECIDE consortium aims to deliver new clinical decision making tools that enable personalised medicine approaches and ‘smart’ clinical trials design in the future. The SMEs will benefit from the project through the development of systems-based combinatorial biomarkers adapted to formalin fixed paraffin-embedded material, the routine material used in clinical histopathology, hence providing a unique opportunity for marketing and exploitation. SMEs and their academic partners will also develop computational whole body models reflecting drug pharmacodynamics and pharmacokinetics in patient cohorts, providing a unique market niche in the field clinical oncology."
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND

Address

Saint Stephen'S Green 123
2 Dublin

Ireland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 932 803,80

Administrative Contact

Jochen Prehn (Prof.)

Participants (6)

Sort alphabetically

Sort by EU Contribution

Expand all

ONCOMARK LIMITED

Ireland

EU Contribution

€ 508 000

THE QUEEN'S UNIVERSITY OF BELFAST

United Kingdom

EU Contribution

€ 353 442

UNIVERSITE PARIS DESCARTES

France

EU Contribution

€ 362 400

OPTIMATA LTD

Israel

EU Contribution

€ 461 160

PINTAIL LTD

Ireland

EU Contribution

€ 64 800

KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET

Germany

EU Contribution

€ 316 876,20

Project information

Grant agreement ID: 306021

Status

Closed project

  • Start date

    1 November 2012

  • End date

    31 October 2014

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 896 336

  • EU contribution

    € 2 999 482

Coordinated by:

ROYAL COLLEGE OF SURGEONS IN IRELAND

Ireland

This project is featured in...